文献速递白血病淋巴瘤

PU.1和Spi-B缺失诱导的B细胞白血病小鼠模型中的Janus激酶驱动突变

Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B.
PubMed 文献 · Blood Adv · 2018-01-01

在条件性敲除Spi1和Spib基因的小鼠模型中,小鼠发生前体B细胞急性淋巴细胞白血病(B-ALL),中位安乐死时间为18周。对Mb1-CreΔPB小鼠白血病细胞行RNA和全外显子组测序,鉴定出Jak1、Jak3和Ikzf3基因的单核苷酸变异。将Jak3 T844M引入Spi1/Spib缺陷的前体B细胞,足以在低IL-7浓度下促进增殖,并在移植小鼠中促进增殖和白血病样疾病。作者认为Janus激酶突变是白血病发生的继发性驱动因素,与Spi1/Spib缺失协同作用。

要点

  • Spi1/Spib条件性双敲除小鼠可发生B-ALL,中位安乐死时间为18周。
  • 白血病细胞中鉴定出Jak1、Jak3和Ikzf3基因的单核苷酸变异。
  • Jak3 T844M足以在低IL-7下促进Spi1/Spib缺陷前体B细胞增殖。

核心结论

  • Janus激酶突变代表与Spi1/Spib缺失协同作用的白血病发生继发性驱动因素,该小鼠模型是研究B-ALL克隆演化的有用工具。

研究设计与样本

  • 使用小鼠模型在发育中的B细胞条件性敲除Spi1和Spib基因。
  • 对Mb1-CreΔPB小鼠分离的白血病细胞进行RNA测序和全外显子组测序。

主要发现

  • Mb1-CreΔPB小鼠发生B-ALL,中位安乐死时间为18周。
  • 在Jak1、Jak3和Ikzf3基因中鉴定出导致氨基酸序列改变的单核苷酸变异。
  • Jak3突变导致假激酶域(R653H、V670A)和激酶域(T844M)的氨基酸替换。
  • 将Jak3 T844M引入Spi1/Spib缺陷前体B细胞,足以在培养中响应低IL-7浓度促进增殖,并在移植小鼠中促进增殖和白血病样疾病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Precursor B-cell acute lymphoblastic leukemia (B-ALL) is associated with recurrent mutations that occur in cancer-initiating cells. There is a need to understand how driver mutations influence clonal evolution of leukemia. The E26-transformation-specific (ETS) transcription factors PU.1 and Spi-B (encoded by Spi1 and Spib) execute a critical role in B-cell development and serve as complementary tumor suppressors. Here, we used a mouse model to conditionally delete Spi1 and Spib genes in developing B cells. These mice developed B-ALL with a median time to euthanasia of 18 weeks. We performed RNA and whole-exome sequencing (WES) on leukemias isolated from Mb1-CreΔPB mice and identified single nucleotide variants (SNVs) in Jak1, Jak3, and Ikzf3 genes, resulting in amino acid sequence changes. Jak3 mutations resulted in amino acid substitutions located in the pseudo-kinase (R653H, V670A) and in the kinase (T844M) domains. Introduction of Jak3 T844M into Spi1/Spib-deficient precursor B cells was sufficient to promote proliferation in response to low IL-7 concentrations in culture, and to promote proliferation and leukemia-like disease in transplanted mice. We conclude that mutations in Janus kinases represent secondary drivers of leukemogenesis that cooperate with Spi1/Spib deletion. This mouse model represents a useful tool to study clonal evolution in B-ALL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Batista CR, Lim M, Laramée AS, et al. Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B. Blood Adv. 2018. PMID: 30355579. doi:10.1182/bloodadvances.2018019950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。